VCP Proteostasis Modulation is a novel therapeutic strategy targeting the Valosin Containing Protein (VCP/p97), a genetically validated AAA+ ATPase that is mutated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and inclusion body myopathy. VCP is essential for protein quality control, ER-associated degradation (ERAD), autophagosome maturation, and DNA repair — all pathways critically impaired in neurodegenerative disease.
VCP mutations cause a spectrum of neurodegenerative disorders[1][2]:
The strong genetic evidence linking VCP to neurodegeneration makes it a compelling therapeutic target.
VCP functions as a molecular segregase that uses ATP hydrolysis to extract ubiquitinated substrates from membranes, protein complexes, and chromatin[3][4]:
In ALS/FTD with VCP mutations:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | First-in-class mechanism targeting genetically validated VCP |
| Mechanistic Rationale | 9 | Strong genetic evidence + multiple preclinical studies on proteostasis |
| Addresses Root Cause | 9 | Targets core proteostasis dysfunction in ALS/FTD |
| Delivery Feasibility | 6 | Small molecule feasible; BBB penetration optimization needed |
| Safety Plausibility | 6 | Modulation preferred over complete inhibition; toxicity risk |
| Combinability | 8 | Synergizes with autophagy enhancers, proteasome modulators |
| Biomarker Availability | 7 | p75 ECD, CSF NfL, aggregate burden imaging |
| De-risking Path | 7 | iPSC neurons from VCP mutation carriers available |
| Multi-disease Potential | 8 | ALS, FTD, IBM, and PD share VCP-related proteostasis defects |
| Patient Impact | 8 | Addresses fundamental mechanism in genetically predisposed |
| Total | 76/100 |
Novel Target — VCP is a genetically validated target with no current therapeutic programs specifically targeting this mechanism in neurodegeneration.
| Disease | Relevance |
|---|---|
| Amyotrophic Lateral Sclerosis | Primary — VCP mutations cause familial ALS |
| Frontotemporal Dementia | Primary — VCP mutations cause FTD |
| Inclusion Body Myopathy | Primary — hallmark of VCP disease |
| Parkinson's Disease | Secondary — VCP variants are risk factors |
| Alzheimer's Disease | Low — not a primary genetic risk |
Small Molecule VCP Modulators:
Alternative Approaches:
VCP modulation could be combined with:
| Milestone | Timeline | Cost |
|---|---|---|
| iPSC motor neuron generation from VCP carriers | Months 1-4 | $400K |
| VCP ATPase assay development | Months 2-6 | $300K |
| Compound library screening | Months 5-10 | $600K |
| Lead optimization and in vitro PK | Months 8-18 | $1.2M |
| Phase 1 Total | $2.5M |
| Milestone | Timeline | Cost |
|---|---|---|
| GLP toxicology | Months 16-24 | $2.0M |
| IND-enabling studies | Months 20-28 | $1.5M |
| Clinical trial design | Months 24-32 | $500K |
| Phase 2 Total | $4.0M |
| Milestone | Timeline | Cost |
|---|---|---|
| Phase 1 first-in-human | Months 30-40 | $3.5M |
| Phase 2 efficacy signal | Months 38-52 | $10M |
| Phase 3 registration trial | Months 50-60 | $25M |
| Phase 3 Total | $38.5M |
Total Program Cost: $45M over 60 months
| Risk | Probability | Impact | Mitigation |
|---|---|---|---|
| Target engagement insufficient | Medium | High | Multiple readouts; iterative optimization |
| Off-target toxicity | Medium | High | Early safety pharmacology |
| Lack of efficacy signal | Medium | High | Genetic enrichment strategy |
| BBB penetration | Medium | Medium | Partner with BBB delivery experts |
Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010. ↩︎
Wong TH, Pottier C, Rizzu P, et al. VCP mutations in a Dutch cohort of patients with familial ALS and F. Neurology Genetics. 2020. ↩︎
Meyer H, Bug M, Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nature Cell Biology. 2012. ↩︎
Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant VCP. Nature Genetics. 2004. ↩︎
Buchan JR, Kolaitis RM, Taylor JP, et al. Eukaryotic stress granules are dynamically regulated by VCP. Cell. 2013. ↩︎
Nalbandian A, Llewellyn KJ, Kitazawa M, et al. The homozygote VCP(R155H/R155H) mouse model exhibits systemic autophagy deficiency and motor neuron degeneration. Neurobiology of Disease. 2012. ↩︎